Dimension INX

Dimension Inx is a biomaterials platform company that designs and develops therapeutic products aimed at restoring tissue and organ function. The company's proprietary biomaterials and 3D-printing platform allow it to engineer three-dimensional microenvironments that direct cell behavior, serving as therapeutic interventions. Dimension Inx takes a materials-centric approach, enabling biofunctionality without compromising manufacturability.

Dimension Inx's core technology involves precisely tuning biomaterials to create clinical solutions that would not be possible otherwise. The company utilizes a unique additive manufacturing process to rapidly produce regenerative structures capable of addressing complex issues. This bottom-up approach directly extrudes 3D "paints" that dry instantaneously, eliminating the need for post-processing. By combining different types of paints, Dimension Inx can create gradient materials, such as a hybrid of paints used for bone tissue and cartilaginous tissue.

One of Dimension Inx's notable products is CMFlex, a 3D-printed synthetic bone graft that received FDA 510(k) clearance in December 2022. CMFlex utilizes a proprietary, microstructurally porous composite material called Hyperelastic Bone, comprising hydroxyapatite particles and biodegradable polylactide-co-glycolide (PLG) polymer. This unique, easily deployable bone repair material can be sized for each patient and is capable of absorbing fluid, controlling bleeding during surgery while assisting the bone remodeling process post-implantation.

Key customers and partnerships

In October 2023, CMFlex was successfully used in its first clinical cases, including mandibular angle augmentation and maxillary segmental osteotomy surgeries. Surgeons reported that CMFlex offered excellent handling characteristics, allowing them to easily cut and shape the graft to match the defect site. The product has also been used in several socket preservation surgeries for future dental implant placement, impressing clinicians with its ability to promote hemostasis and simplify the implantation process.

Dimension Inx has partnered with various companies in the medtech and biotech spaces, engaging in joint development partnerships to create new products. The company has also collaborated with institutions like Northwestern University and the Ann & Robert H. Lurie Children's Hospital of Chicago to explore novel approaches, such as the development of a bioprosthetic ovary.

In November 2022, Dimension Inx and Lurie Children's Hospital were jointly awarded an NIH Exploratory/Developmental Research Grant to further investigate the in vitro growth and maturation of ovarian follicles, aiming to develop a more accessible and affordable infertility preservation intervention.